Also known as: CLL/SLL
Six-year SEQUOIA trial data show zanubrutinib sustains a progression-free survival advantage (74% vs 32%) over bendamustine-rituximab in CLL without del(17p). Benefit extends to high-risk del(17p) patients.
The FDA approved acalabrutinib plus venetoclax for previously untreated CLL/SLL based on phase 3 AMPLIFY data. The fixed 14-month regimen improved progression-free survival versus chemotherapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06319456 |
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. |
RECRUITING | PHASE3 |
| NCT06104566 |
Global Trial in APG2575 for Patients With CLL/SLL |
RECRUITING | PHASE3 |
| NCT05665062 |
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies |
ACTIVE_NOT_RECRUITING | PHASE1 |
